0.07
+0(+0.00%)
Currency In USD
| Previous Close | 0.07 |
| Open | 0.07 |
| Day High | 0.07 |
| Day Low | 0.07 |
| 52-Week High | 1.78 |
| 52-Week Low | 0.03 |
| Volume | 400 |
| Average Volume | 15,025 |
| Market Cap | 272,518 |
| PE | -0.02 |
| EPS | -3.74 |
| Moving Average 50 Days | 0.07 |
| Moving Average 200 Days | 0.42 |
| Change | 0 |
If you invested $1000 in IMAC Holdings, Inc. (BACK) since IPO date, it would be worth $0.65 as of September 08, 2025 at a share price of $0.072. Whereas If you bought $1000 worth of IMAC Holdings, Inc. (BACK) shares 5 years ago, it would be worth $3.29 as of September 08, 2025 at a share price of $0.072.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IMAC Holdings Announces Research Collaboration with Vanderbilt University Medical Center to Advance Immuno-Oncology Biomarker Discovery
GlobeNewswire Inc.
Aug 07, 2025 8:05 PM GMT
Project will leverage Ignite Proteomics’ reverse-phase protein array (RPPA) platform to profile tumor-immune signaling in breast-cancer samples Golden, CO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc.
Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference
GlobeNewswire Inc.
Feb 24, 2025 1:15 PM GMT
Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response t
Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay
GlobeNewswire Inc.
Feb 19, 2025 2:15 PM GMT
Golden, CO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (Nasdaq: BACK), today announced the completed transfer of Proprietary Laboratory Analyses (PLA) code 0249U – originally issued to Theralink Tec